Literature DB >> 16987481

[Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up].

Francisco Buitrago Ramírez1, Lourdes Cañón Barroso, Natalio Díaz Herrera, Eloísa Cruces Muro, Belén Bravo Simón, Ignacio Pérez Sánchez.   

Abstract

BACKGROUND AND
OBJECTIVE: Framingham-REGICOR and SCORE (Systematic Coronary Risk Evaluation) are 2 functions charts recommended to estimate the cardiovascular risk stratification in Spain. The aim of the present study was to validate to 10 years the SCORE and REGICOR functions charts in 40 to 65 years old population. PATIENTS AND
METHOD: 608 patients (56.7% female) with non evidence of cardiovascular disease were included in the present study. Patients were classified as high risk by REGICOR (> or = 10%) and by SCORE (> or = 5%) functions.
RESULTS: The 90.6% of the population (551 subjects) did not experienced any cardiovascular events during the 10 years follow-up. The REGICOR function chart underestimated the coronary risk (4.9% vs 7.9%; p < 0.001), whereas the SCORE overestimated the cardiovascular risk of death (2.1% vs 1.5%; p < 0.001). In the SCORE function, the average risk of patients with events was 6.1%, whereas the average risk of patients without events was 2.0% (p < 0.001) and 7.1% vs 4.8% (p < 0.001) in the REGICOR equation. The SCORE function obtained better validity criteria than REGICOR with a sensibility of 66.7% (95% confidence interval [CI], 66.2-67.2), especificity of 91.7%, (95% CI, 91.2-92.2) positive likelihood ratio of 8 (95% CI, 7.5-8.5), and eficacy of 91.1% (95% CI, 90.6-91.6). These results were observed in both sexes: women -sensibility: 33.3% (95% CI, 32.4-34.2); especificity: 97.4% (95% CI, 96.5-98.3)- and men -sensibility: 83.3% (95% CI, 82.7-83.9); especificity: 84.0% (95% CI, 83.4-84.6).
CONCLUSIONS: The SCORE equation obtains better validity criteria than the REGICOR equation both in the total population and in males and females separately. These results make the SCORE function a powerful tool to estimate the cardiovascular risk.

Entities:  

Mesh:

Year:  2006        PMID: 16987481     DOI: 10.1157/13092437

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  5 in total

1.  Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients.

Authors:  Manuel A Gómez-Marcos; Gonzalo Grandes; José A Iglesias-Valiente; Alvaro Sánchez; Imanol Montoya; Luis García-Ortiz
Journal:  Int J Environ Res Public Health       Date:  2009-11-11       Impact factor: 3.390

2.  Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients.

Authors:  Manuel A Gómez-Marcos; Carlos Martínez-Salgado; Carlos Martin-Cantera; José I Recio-Rodríguez; Yolanda Castaño-Sánchez; Maria Giné-Garriga; Emiliano Rodriguez-Sanchez; Luis García-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2009-05-11       Impact factor: 2.298

3.  Peripheral Arterial Disease study (PERART): prevalence and predictive values of asymptomatic peripheral arterial occlusive disease related to cardiovascular morbidity and mortality.

Authors:  María Teresa Alzamora; José Miguel Baena-Díez; Marta Sorribes; Rosa Forés; Pere Toran; Marisa Vicheto; Guillem Pera; María Dolores Reina; Carlos Albaladejo; Judith Llussà; Magda Bundó; Amparo Sancho; Antonio Heras; Joan Rubiés; Juan Francisco Arenillas
Journal:  BMC Public Health       Date:  2007-12-11       Impact factor: 3.295

4.  SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis.

Authors:  Carmen Gómez-Vaquero; Alfonso Corrales; Andrea Zacarías; Javier Rueda-Gotor; Ricardo Blanco; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

5. 

Authors:  Carlos Brotons Cuixart; José Juan Alemán Sánchez; José Ramón Banegas Banegas; Carlos Fondón León; José María Lobos-Bejarano; Enrique Martín Rioboó; Jorge Navarro Pérez; Domingo Orozco-Beltrán; Fernando Villar Álvarez
Journal:  Aten Primaria       Date:  2018-05       Impact factor: 1.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.